ArticleJournal of the American Society of Nephrology : JASN2017
Global Cardiovascular and Renal Outcomes of Reduced GFR.
Abstract read
In one paragraph
Article in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease.Kidney international · 2021Trial
- Serum bicarbonate and cardiovascular events in hypertensive adults: results from the Systolic Blood Pressure Intervention Trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020Trial
- Chronic Kidney Disease Severity Is Associated With Selective Expansion of a Distinctive Intermediate Monocyte Subpopulation.Frontiers in immunology · 2018Trial
- Studying the Comorbidity of Impaired eGFR With Diabetes, Hypertension, and Cardiovascular Diseases in the Tabari Cohort Population.Public health challenges · 2026Article
- Estrogen protects female mice with chronic kidney disease from fibroblast growth factor 23-induced left ventricular hypertrophy.Kidney international · 2026Article
- A kidney-protective mechanism via cellular oxidative stress reduction induced by CD5L protein.Cell death discovery · 2026Article
- Family History of Kidney Failure, APOL1 Risk Variants, Social Determinants of Health, and Risk of CKD Progression: Findings From the CRIC Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026Observational
- MUC20 alleviates kidney fibrosis by modulating pyroptosis through the MET/RAS/STING axis.Theranostics · 2026Article
- The Role of DNA Methyltransferases in Urinary System Diseases.Cancer innovation · 2025Review
- CKD Prevalence and Associated Factors in Jamaica.Kidney international reports · 2025Article
- Article
- Comparison of estimated glomerular filtration rate equations on prediction of mortality, kidney failure and acute kidney injury.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
- Elevated Sirtuin 1 Levels in Patients with Chronic Kidney Disease, Including on Peritoneal Dialysis: Associations with Cardiovascular Risk and Peritoneal Fibrosis.International journal of molecular sciences · 2025Article
- Impaired vascular function in patients with chronic kidney disease who have elevated symmetric dimethylarginine but not asymmetric dimethylarginine.American journal of physiology. Renal physiology · 2025Article
- Probiotics restore enteric HDL3 secretion and improve prognosis in patients with end-stage renal disease.iMeta · 2025Article
- Nonatherosclerotic Cardiovascular Disease in Chronic Kidney Disease.Cardiology clinics · 2025Review
- Association of neutrophil-to-albumin ratio with all-cause and cardiovascular mortality in community-dwelling individuals with chronic kidney disease: evidence from the NHANES 1999-2018.BMC cardiovascular disorders · 2025Article
- Cross-country inequalities in the epidemiology of chronic kidney disease due to type 2 diabetes mellitus, 1990-2021: findings from the global burden of disease study 2021.Diabetology & metabolic syndrome · 2025Article
- Association of combined left and right handgrip strength with new-onset chronic kidney disease in middle-aged and older adults: a nationwide multicenter cohort study.BMC public health · 2025Observational
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
93 authors.
Bernadette ThomasInstitute for Health Metrics and Evaluation, bathomas@uw.edu.
Kunihiro MatsushitaDepartment of Epidemiology and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Kalkidan Hassen AbateJimma University, Jimma, Ethiopia.
Ziyad Al-AlyWashington University in St. Louis, St. Louis, Missouri.
Johan ÄrnlövDivision of Family Medicine and Primary Care, Department of Neurobiology, Care Science and Society, Karolinska Institutet, Huddinge, Sweden.
Kei AsayamaTeikyo University School of Medicine, Tokyo, Japan.
Robert AtkinsBaker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Alaa BadawiPublic Health Agency of Canada, Toronto, Ontario, Canada.
Shoshana H BallewDepartment of Epidemiology and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Amitava BanerjeeFarr Institute of Health Informatics Research, University College London, London, England, United Kingdom.
Lars BarregårdDepartment of Occupational and Environmental Health, University of Gothenburg, Gothenburg, Sweden.
Elizabeth Barrett-ConnorDepartment of Family Medicine and Public Health.
Sanjay BasuStanford University, Stanford, California.
Aminu K BelloDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Isabela BensenorUniversity of São Paulo, São Paulo, Brazil.
Jaclyn BergstromDepartment of Family Medicine and Public Health.
Boris BikbovDepartment of Nephrology Issues of Transplanted Kidney, Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russia.
Christopher BlosserInternal Medicine, Nephrology, University of Washington, Seattle, Washington.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
Juan-Jesus CarreroDepartment of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Steve ChadbanAustralia and New Zealand Dialysis and Transplant Registry, Adelaide, South Australia.
Massimo CirilloUniversity of Salerno, Baronissi, Italy.
Monica CortinovisIstituto Di Ricovero E Cura A Carattere Scientifico, Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy.
Karen CourvilleIstituto Di Ricovero E Cura A Carattere Scientifico, Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy.
Lalit DandonaInstitute for Health Metrics and Evaluation.
Rakhi DandonaInstitute for Health Metrics and Evaluation.
Kara EstepInstitute for Health Metrics and Evaluation.
João FernandesCenter for Biotechnology and Fine Chemistry, Associate Laboratory, Faculty of Biotechnology, Catholic University of Portugal, Porto, Portugal.
Florian FischerBielefeld University, Bielefeld, Germany.
Caroline FoxNational Heart, Lung, and Blood Institute, Framingham, MA.
Ron T GansevoortUniversity Medical Center Groningen, Groningen, Netherlands.
Philimon N GonaUniversity of Massachusetts Boston, Boston, MA.
Orlando M GutierrezSchool of Medicine and.
Samer HamidiHamdan Bin Mohammed Smart University, Dubai, United Arab Emirates.
Sarah Wulf HansonInstitute for Health Metrics and Evaluation.
Jonathan HimmelfarbInternal Medicine, Nephrology, University of Washington, Seattle, Washington.
Simerjot K JassalVeterans Affairs, University of California, San Diego, San Diego, California.
Sun Ha JeeDepartment of Epidemiology and Health Promotion, Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, South Korea.
Vivekanand JhaGeorge Institute for Global Health, New Delhi, India.
Aida Jimenez-CoronaDepartment of Ocular Epidemiology and Visual Health, Institute of Ophthalmology Conde de Valencia, Mexico City, Mexico.
Jost B JonasDepartment of Ophthalmology, Medical Faculty Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim, Germany.
Andre Pascal KengneSouth African Medical Research Council, Cape Town, South Africa.
Yousef KhaderJordan University of Science and Technology, Irbid, Jordan.
Young-Ho KhangCollege of Medicine, Seoul National University, Seoul, South Korea.
Yun Jin KimSouthern University College, Skudai, Malaysia.
Barbara KleinDepartment of Ophthalmology and Visual Sciences and.
Ronald KleinDepartment of Ophthalmology and Visual Sciences and.
Yoshihiro KokuboDepartment of Preventive Cardiology, National Cerebral and Cardiovascular Center, Suita, Japan.
Dhaval KolteDivision of Cardiology, Brown University, Providence, Rhode Island.
Kristine LeeOphthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI.
Andrew S LeveyDivision of Nephrology, Tufts Medical Center, Boston, MA.
Yongmei LiGeneral Internal Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, CA.
Paulo LotufoUniversity of São Paulo, São Paulo, Brazil.
Hassan Magdy Abd El RazekMansoura Faculty of Medicine, Mansoura, Egypt.
Walter MendozaUnited Nations Population Fund, Lima, Peru.
Hirohito MetokiTohoku University, Sendai, Japan.
Yejin MokDepartment of Epidemiology and Health Promotion, Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, South Korea.
Isao MurakiOsaka Medical Center for Cancer and Cardiovascular Diseases Prevention, Osaka, Japan.
Paul M MuntnerDepartments of Epidemiology and.
Hiroyuki NodaDepartment of Social and Environmental Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Takayoshi OhkuboTeikyo University School of Medicine, Tokyo, Japan.
Alberto OrtizIIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain.
Norberto PericoIstituto Di Ricovero E Cura A Carattere Scientifico, Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy.
Kevan PolkinghorneNephrology, Monash Medical Centre, Melbourne, Victoria, Australia.
Rajaa Al-RadaddiMinistry of Health, Jeddah, Saudi Arabia.
Giuseppe RemuzziIstituto Di Ricovero E Cura A Carattere Scientifico, Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy.
Gregory RothInstitute for Health Metrics and Evaluation.
Dietrich RothenbacherInstitute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
Michihiro SatohTohoku University, Sendai, Japan.
Kai-Uwe SaumDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
Monika SawhneyMarshall University, Huntington, WV.
Ben SchöttkerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
Anoop ShankarSt. Louis, MO.
Michael ShlipakGeneral Internal Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, CA.
Diego Augusto Santos SilvaFederal University of Santa Catarina, Florianopolis, Brazil.
Hideaki ToyoshimaHealth Care Center of Anjo Kosei Hospital, Anjo City, Japan.
Kingsley UkwajaDepartment of Internal Medicine, Federal Teaching Hospital, Abakaliki, Nigeria.
Mitsumasa UmesawaIbaraki Prefectural University of Health Sciences, Ibaraki, Japan.
Stein Emil VollsetCenter for Disease Burden, Norwegian Institute of Public Health, Bergen, Norway.
David G WarnockMedicine, University of Alabama at Birmingham, Birmingham, AL.
Andrea WerdeckerCompetence Center Mortality-Follow-Up of the German National Cohort, Federal Institute for Population Research, Wiesbaden, Germany.
Kazumasa YamagishiDepartment of Public Health Medicine, University of Tsukuba, Tsukuba, Japan.
Yuichiro YanoDepartment of Preventive Medicine, Northwestern University, Chicago, IL; and.
Naohiro Yonemoto**************Department of Biostatistics, School of Public Health, Kyoto University, Kyoto, Japan.
Maysaa El Sayed ZakiMansoura Faculty of Medicine, Mansoura, Egypt.
Mohsen NaghaviInstitute for Health Metrics and Evaluation.
Mohammad H ForouzanfarInstitute for Health Metrics and Evaluation.
Christopher J L MurrayInstitute for Health Metrics and Evaluation.
Josef CoreshDepartment of Epidemiology and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Theo VosInstitute for Health Metrics and Evaluation.
Global Burden of Disease 2013 GFR Collaborators
CKD Prognosis Consortium
Global Burden of Disease Genitourinary Expert Group
Funding
VCID and Stroke in a Bi-racial National CohortU01NS041588 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CUSHMAN, MARY, HOWARD, GEORGE · 2002 to 2022
$96.0MInstitute for Clinical and Translational Research (UL1)UL1RR025005 · NCRR · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2007 to 2011
$75.8MZDV VS ZDV + DDL VS ZDV + DDL + NVP IN ASYMPTOMATIC HIV PATIENTSM01RR000040 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 1985 to 2006
$21.1MUniversity of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANANDA BASU · 2013 to 2026
$19.5MTHE EPIDEMIOLOGY OF AGE-RELATED OCULAR DISEASEU10EY006594 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI KLEIN, RONALD · 1987 to 2018
$17.3MREGARDS - MI StudyR01HL080477 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEVITAN, EMILY B, SAFFORD, MONIKA M · 2006 to 2020
$11.6MSTUDY OF RISK FACTORS FOR OSTEOPOROSIS IN THE ELDERLYR37AG007181 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BARRETT-CONNOR, ELIZABETH L · 1987 to 2010
$5.4MGENDER DIFFERENCES IN OSTEOPOROSISR01AG007181 · NIA · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI BARRETT-CONNOR, ELIZABETH L · 1999 to 2002
$1.6MAdjunctive Use of Apyrase to Fibrinolytic TherapyR44HL095169 · NHLBI · APT THERAPEUTICS, INC. · PI CHEN, RIDONG · 2012 to 2013
$1.3MEPIDEMIOLOGY OF NIDDM AND IGT IN AN ADULT COMMUNITYR01DK031801 · NIDDK · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI BARRETT-CONNOR, ELIZABETH L · 1986 to 2000
$606kSUBCLINICAL CARDIOVASCULAR DISEASE COORDINATING CENTER-N01HC95159-268095159N01HC095159 · HC · UNIVERSITY OF WASHINGTON · PI KRONMAL, RICHARD A · 1999 to 2006
$304kAdjunctive Use of Apyrase to Fibrinolytic TherapyR43HL095169 · NHLBI · APT THERAPEUTICS, INC. · PI CHEN, RIDONG · 2009 to 2009
$226kNCRR NIH HHS M01 RR000040NCRR NIH HHS UL1 RR025005NEI NIH HHS U10 EY006594NHLBI NIH HHS HHSN268201100005CNHLBI NIH HHS HHSN268201100005GNHLBI NIH HHS HHSN268201100005INHLBI NIH HHS HHSN268201100006CNHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100007INHLBI NIH HHS HHSN268201100008CNHLBI NIH HHS HHSN268201100008INHLBI NIH HHS HHSN268201100009CNHLBI NIH HHS HHSN268201100009INHLBI NIH HHS HHSN268201100010CNHLBI NIH HHS HHSN268201100011CNHLBI NIH HHS HHSN268201100011INHLBI NIH HHS HHSN268201100012CNHLBI NIH HHS N01 HC025195NHLBI NIH HHS N01 HC095159NHLBI NIH HHS N01 HC095169NHLBI NIH HHS R01 HL080477NIA NIH HHS R01 AG007181NIA NIH HHS R37 AG007181NIDDK NIH HHS P30 DK079626NIDDK NIH HHS R01 DK031801NINDS NIH HHS U01 NS041588
Abstract
The burden of premature death and health loss from ESRD is well described. Less is known regarding the burden of cardiovascular disease attributable to reduced GFR. We estimated the prevalence of reduced GFR categories 3, 4, and 5 (not on RRT) for 188 countries at six time points from 1990 to 2013. Relative risks of cardiovascular outcomes by three categories of reduced GFR were calculated by pooled random effects meta-analysis. Results are presented as deaths for outcomes of cardiovascular disease and ESRD and as disability-adjusted life years for outcomes of cardiovascular disease, GFR categories 3, 4, and 5, and ESRD. In 2013, reduced GFR was associated with 4% of deaths worldwide, or 2.2 million deaths (95% uncertainty interval [95% UI], 2.0 to 2.4 million). More than half of these attributable deaths were cardiovascular deaths (1.2 million; 95% UI, 1.1 to 1.4 million), whereas 0.96 million (95% UI, 0.81 to 1.0 million) were ESRD-related deaths. Compared with metabolic risk factors, reduced GFR ranked below high systolic BP, high body mass index, and high fasting plasma glucose, and similarly with high total cholesterol as a risk factor for disability-adjusted life years in both developed and developing world regions. In conclusion, by 2013, cardiovascular deaths attributed to reduced GFR outnumbered ESRD deaths throughout the world. Studies are needed to evaluate the benefit of early detection of CKD and treatment to decrease these deaths.
Indexed as
Glomerular Filtration RateCardiovascular DiseasesGlobal HealthHumansKidneyKidney DiseasesRisk AssessmentRisk Factorscardiovascular diseasechronic dialysischronic kidney diseaseend stage kidney diseaseEpidemiology and outcomes
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.